for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amgen, Inc.

AMGN.O

Latest Trade

204.66USD

Change

1.77(+0.87%)

Volume

1,502,787

Today's Range

202.60

 - 

204.80

52 Week Range

166.30

 - 

211.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Health Canada Approves Evenity For Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Oct 8 (Reuters) - Amgen Inc <AMGN.O>::HEALTH CANADA APPROVES EVENITY FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK FOR FRACTURE.

Amgen Announces Positive Results From Two Phase 3 Blincyto® Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

Sept 24 (Reuters) - Amgen Inc <AMGN.O>::AMGEN ANNOUNCES POSITIVE RESULTS FROM TWO PHASE 3 BLINCYTO® (BLINATUMOMAB) STUDIES IN PEDIATRIC PATIENTS WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA.AMGEN INC - PHASE 3 '215 AND CHILDREN'S ONCOLOGY GROUP (COG) STUDIES BOTH STOPPED EARLY DUE TO TREATMENT BENEFIT OF BLINCYTO OVER CHEMOTHERAPY.AMGEN INC - ENROLLMENT WAS TERMINATED EARLY DUE TO ENCOURAGING EFFICACY IN BLINCYTO ARM AND WAS BASED ON A RECOMMENDATION FROM INDEPENDENT DMC.AMGEN INC - BLINCYTO ADVERSE EVENTS OBSERVED IN PHASE 3 20120215 AND COG AALL1331 STUDIES WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF BLINCYTO..AMGEN - RESULTS OF OPEN-LABEL, RANDOMIZED, CONTROLLED GLOBAL MULTICENTER PHASE 3 TRIAL SHOWED PRIMARY ENDPOINT OF EVENT-FREE SURVIVAL MET.

Amgen Announces Phase 3 Candor Study Combining Kyprolis And Darzalex Meets Primary Endpoint Of Progression-Free Survival

Sept 13 (Reuters) - Amgen Inc <AMGN.O>::AMGEN ANNOUNCES PHASE 3 CANDOR STUDY COMBINING KYPROLIS® (CARFILZOMIB) AND DARZALEX® (DARATUMUMAB) MEETS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL.AMGEN INC - THERE WAS A HIGHER FREQUENCY OF ADVERSE EVENTS REPORTED IN KDD, A THREE-AGENT REGIMEN, THAN IN KD, A TWO-AGENT REGIMEN.AMGEN - REGIMEN RESULTED IN A 37% REDUCTION IN RISK OF PROGRESSION OR DEATH IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH KDD.

Amgen Highlights New Data From Kyprolis (Carfilzomib) And Oncology Pipeline At IMW 2019

Sept 12 (Reuters) - Amgen Inc <AMGN.O>::AMGEN HIGHLIGHTS NEW DATA FROM KYPROLIS® (CARFILZOMIB) AND ONCOLOGY PIPELINE AT IMW 2019.AMGEN INC - DATA PRESENTED FROM ANTI-BCMA BITE® AND MCL-1 PROGRAMS.AMGEN INC - A PHASE 1 DOSE ESCALATION STUDY OF AMG 701 IS UNDERWAY WITH DATA EXPECTED FOR PRESENTATION IN 2020..AMGEN INC - PHASE 1 DOSE ESCALATION CLINICAL TRIAL FOR AMG 397 (NCT03465540 ) IS ON A CLINICAL HOLD TO EVALUATE A SAFETY SIGNAL FOR CARDIAC TOXICITY.AMGEN INC - AMG 176 PHASE 1 TRIAL (NCT02675452 ) HAS BEEN PLACED ON A VOLUNTARY HOLD FOR NEW ENROLLMENT..AMGEN INC - EXPLORING INTERMITTENT DOSING OPTIONS WITH AMG 420 THAT COULD BE EVALUATED FOLLOWING PHASE 1B STUDY..

Toronto Innovation Acceleration Partners Announces Strategic Partnership With Amgen

Sept 9 (Reuters) - Toronto Innovation Acceleration Partners::TIAP-AMGEN & TIAP WILL JOINTLY FUND NASCENT TECHNOLOGIES MANAGED BY TIAP ON BEHALF OF TORONTO-BASED MEMBER INSTITUTIONS .TORONTO INNOVATION ACCELERATION PARTNERS ANNOUNCES STRATEGIC PARTNERSHIP WITH AMGEN.TORONTO INNOVATION ACCELERATION PARTNERS SAYS UNDER TERMS, TIAP AND AMGEN WILL JOINTLY FUND NASCENT TECHNOLOGIES.

Alexion Pharmaceuticals Says European Patent Office To Not Grant Co Patent Application Relating To Pharmaceutical Composition Of Soliris

Sept 5 (Reuters) - Alexion Pharmaceuticals Inc <ALXN.O>::ALEXION PHARMACEUTICALS - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF SOLIRIS (ECULIZUMAB).ALEXION PHARMACEUTICALS INC - WILL EVALUATE OPTION TO APPEAL THE EUROPEAN PATENT OFFICE’S DECISION.ALEXION PHARMA - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF MATTER OF SOLIRIS (ECULIZUMAB).

Sanofi Says Court Rules In Favor Of Sanofi And Regeneron In Ongoing Praluent (Alirocumab) Patent Litigation

Aug 28 (Reuters) - Sanofi SA <SASY.PA>::SANOFI : U.S. DISTRICT COURT INVALIDATES AMGEN PATENT CLAIMS TARGETING PCSK9.SANOFI - COURT RULES IN FAVOR OF SANOFI AND REGENERON IN ONGOING PRALUENT (ALIROCUMAB) PATENT LITIGATION.

Amgen On Anticipated FTC Concerns Says Highly Confident About Deal For Otezla

Aug 26 (Reuters) - Amgen Inc <AMGN.O>::AMGEN EXECUTIVE ON ANTICIPATED FTC CONCERNS SAYS HIGHLY CONFIDENT ABOUT DEAL FOR OTEZLA: CONF. CALL.

Amgen sees SG&A, R&D expenses up in 2020 after Otezla deal

Aug 26 (Reuters) - Amgen <AMGN.O>::EXEC SEES 2020 NON-GAAP SG&A EXPENSES UP $600-700 MILLION DUE TO ONGOING COST OF OTEZLA-CONF. CALL.EXEC SEES 2020 NON-GAAP RESEARCH AND DEVELOPMENT OPERATING EXPENSES UP $500 MILLION -CONF. CALL.EXEC SEES 2020 SHARE REPURCHASES CONSISTENT WITH 2015-2018 REPURCHASES, EXCLUDING 2018 TENDER-CONF. CALL.

Amgen To Acquire Otezla For $13.4 Bln

Aug 26 (Reuters) - Amgen Inc <AMGN.O>::AMGEN TO ACQUIRE OTEZLA® FOR $13.4 BILLION IN CASH, OR APPROXIMATELY $11.2 BILLION NET OF ANTICIPATED FUTURE CASH TAX BENEFITS.AMGEN INC - AMGEN WILL FINANCE TRANSACTION WITH CURRENT BALANCE SHEET CASH AND EXPECTS TO RETAIN ITS INVESTMENT GRADE CREDIT RATING.AMGEN INC - BELIEVES ACQUISITION OF OTEZLA TO BE IMMEDIATELY NON-GAAP EPS ACCRETIVE.AMGEN INC - AMGEN'S CAPITAL ALLOCATION PRIORITIES WILL REMAIN UNCHANGED.AMGEN INC - DEAL FOR ABOUT $11.2 BILLION, NET OF PRESENT VALUE OF $2.2 BILLION IN ANTICIPATED FUTURE CASH TAX BENEFITS.AMGEN INC - EXPECTS AT LEAST LOW DOUBLE-DIGIT OTEZLA SALES GROWTH, ON AVERAGE, OVER NEXT FIVE YEARS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up